A Shanghai Henlius Biotech study demonstrates equivalence for its bevacizumab candidate, and Celltrion moves forward with a trial for a SARS-CoV-2 candidate.
Shanghai Henlius Biotech reported positive phase 3 clinical study data for its bevacizumab biosimilar candidate (HLX04). The trial compared the biosimilar with reference bevacizumab (Avastin) in combination with the chemotherapy regimens Xelox and mFolfox6 as a first-line treatment for metastatic colorectal cancer (mCRC).
Investigators said HLX04 demonstrated efficacy, safety, and immunogenicity equivalence to Avastin. Potential oncology indications for HLX04, besides colorectal cancer, include advanced, metastatic, or recurrent non–small cell lung cancer.
The trial, HLX04-mCRC03, was a multicenter, randomized, double-blind, parallel controlled study that randomized patients 1:1 to the biosimilar candidate (n = 338) or reference product (n = 337) delivered intravenously (7.5 mg/kg every 3 weeks when combined with XELOX or 5 mg/kg every 2 weeks when combined with mFOLFOX6). The primary end point was progression-free survival (PFS) at week 36.
PFS was 46.4% in the HLX04 group and 50.7% for the reference cohort. Henlius said the group difference was –4.2% and fell within predefined equivalence margins, demonstrating biosimilarity. Investigators said there was no statistically significant difference between the biosimilar candidate and reference drugs in terms of overall survival, PFS, objective response rate, time to response, or duration of response. Safety and immunogenicity profiles also were equivalent.
“The results of the phase 3 study demonstrated the equivalence in efficacy between HLX04 and reference bevacizumab with similar safety and immunogenicity profiles as first-line treatment for mCRC patients. HLX04 will provide an alternative treatment option for cancer patients as a potential biosimilar candidate,” the company said.
Henlius also aims to obtain indications for ophthalmic diseases such as wet age-related macular degeneration and diabetic retinopathy.
Celltrion Group
Biosimilar developer Celltrion Group said it has completed enrollment of 327 patients for a coronavirus disease 2019 (COVID-19) drug candidate phase 2 clinical trial. If results are positive, the company aims to apply for emergency use authorization from the Korean Ministry of Food and Drug Safety.
In preclinical studies, the agent, CT-P59, demonstrated a 100-fold reduction in viral load of SARS-CoV-2, the virus that causes COVID-19, as well as a reduction in lung inflammation.
The phase 2, randomized, double-blind, controlled trial is evaluating CT-P59 in patients with mild and moderate symptoms of COVID-19 in 3 cohorts: placebo, low concentration dose, and high concentration dose. “Results from the trial are expected in the coming weeks,” said Sang Joon Lee, senior executive vice president of Celltrion.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.